{"schema_version":"secwatch.filing_event.v1","accession":"0001559053-23-000025","form_type":"8-K","ticker":"PRTA","cik":"0001559053","company_name":"PROTHENA CORP PUBLIC LTD CO","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.292826+00:00","generated_at":"2026-06-12T08:10:04.373573+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Prothena Q2 net loss $54.6M, revises FY cash guidance up to ~$600M","bullets":["Net loss $54.6M ($1.03/share) vs $41.2M loss in Q2 2022; revenue $4.0M (up from $1.3M).","Cash, equivalents $661.3M at June 30; year-end cash guidance raised to ~$600M midpoint from $512M.","Bristol Myers Squibb exercised $55M option for worldwide rights to PRX005 (anti-tau) in July 2023.","PRX012 Phase 1 topline data expected year-end 2023; IND filing for PRX123 dual vaccine expected year-end.","Billy Dunn (former FDA Office of Neuroscience Director) added to Board."],"urls":{"canonical":"https://secwatch.observer/filing/0001559053-23-000025","json":"https://secwatch.observer/filing/0001559053-23-000025.json","markdown":"https://secwatch.observer/filing/0001559053-23-000025.md","text":"https://secwatch.observer/filing/0001559053-23-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1559053/000155905323000025/0001559053-23-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1559053/000155905323000025/prta-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T08:10:04.373573+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1eec5981ad8bd9a75319a7b3e3d78401caaddd24","claim":"PROTHENA CORP PUBLIC LTD CO updated its the second quarter ended June 30, 2023 guidance (lowered).","evidence_excerpt":"Prothena Corporation plc issued a press release announcing its financial results for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1559053/000155905323000025/0001559053-23-000025-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}